EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Molecular imaging of neuroendocrine tumors: Current applications and future trends

Ivan E Wang, Helen A SaTsu, Allen F Brooks, Rudolf A Werner, Steven P Rowe, Peter J H Scott, Benjamin L Viglianti

Diagnostic and Interventional Imaging · 2025-11 · 106 (11) · 385-393

DOI: 10.1016/j.diii.2025.05.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostic and Interventional Imaging, 2025-11. Verfasst von Ivan E Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Michigan, Ann Arbor MI 48109 USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Molecular Imaging. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NIGMS NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of neuroendocrine neoplasms (NEN), which include neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), has increasing during recent years. The approval of diagnostic single-photon emission computed tomography and positron emission tomography imaging agents for NEN is an important factor in pushing the development of additional agents using new targets to develop patient-specific, targeted, radiopharmaceuticals. Numerous NEN-specific targets exist, including somatostatin receptors, norepinephrine transport substrates, amino acid transport substrates, and glucagon-like peptide-1 receptor analogues, as well as non-specific targets, such as glucose metabolism. Additionally, there are targets that can be used in combination with current agents to further personalize NEN imaging. In well-differentiated gastroenteropancreatic NET, [68Ga]DOTATATE is the first line agent. In pheochromocytoma, paraganglioma, and neuroblastomas [131I]MIBG can also be considered for imaging. [18F]FDOPA is mainly used for midgut NETs but is second line if access to [68Ga]DOTATATE is difficult. In insulinomas, glucagon like peptide-1 receptor agents can be considered with [68Ga]DOTATATE. In medullary thyroid carcinomas, [18F]FDOPA is preferred with or without [68Ga]DOTATATE imaging. In poorly-differentiated NEN/NEC, non-specific agents such as [18F]Fluoro-2-deoxy-d-glucose and [68Ga]fibroblast activation protein inhibitor-04 can be used if somatostatin imaging is insufficient. Urokinase plasminogen activator receptor targeting has been used as a method for risk stratification and can be used in combination with [68Ga]DOTATATE. The use of somatostatin receptor antagonists, bombesin receptor 2, C-X-C motif chemokine receptor-4, and glucose-dependent insulinotropic polypeptide receptor agents are currently in development - with all of them requiring further studies to determine their potential utility. This review analyzes the current landscape of NEN imaging and discusses the emerging agents that can potentially contribute to NEN imaging in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsMolecular ImagingHumansRadiopharmaceuticalsForecasting

Stichwörter der Autor:innen

Fibroblast activation protein inhibitor (FAPI)Neuroendocrine tumorsNuclear medicinePheochromocytoma, Somatostatin

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology, University of Michigan, Ann Arbor MI 48109 USA.
  • Department of Nuclear Medicine, LMU University Hospital 80336 Munich, Germany.
  • Department of Radiology, University of North Carolina, Chapel Hill, NC 27599 USA.
  • Department of Radiology, University of Michigan, Ann Arbor MI 48109 USA. Electronic address: bviglia@med.umich.edu.

Förderung

  • NIBIB NIH HHS
  • NIGMS NIH HHS
  • NIH
  • Neuroendocrine Tumor Research Foundation

Zitieren

APA

Wang, I. E., SaTsu, H. A., Brooks, A. F., Werner, R. A., Rowe, S. P., Scott, P. J. H., & Viglianti, B. L. (2025). Molecular imaging of neuroendocrine tumors: Current applications and future trends. Diagnostic and Interventional Imaging, 106(11), 385-393. https://doi.org/10.1016/j.diii.2025.05.005

Vancouver

Wang IE, SaTsu HA, Brooks AF, Werner RA, Rowe SP, Scott PJH, et al. Molecular imaging of neuroendocrine tumors: Current applications and future trends. Diagnostic and Interventional Imaging. 2025;106(11):385-393. doi:10.1016/j.diii.2025.05.005

BibTeX
@article{Wang2025,
  author = {Wang, Ivan E and SaTsu, Helen A and Brooks, Allen F and Werner, Rudolf A and Rowe, Steven P and Scott, Peter J H and Viglianti, Benjamin L},
  title = {Molecular imaging of neuroendocrine tumors: Current applications and future trends},
  journal = {Diagnostic and Interventional Imaging},
  year = {2025},
  volume = {106},
  number = {11},
  pages = {385--393},
  doi = {10.1016/j.diii.2025.05.005}
}
Kostenlos starten →